FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384156761> ?p ?o ?g. }

• W4384156761 endingPage "102087" @default.
• W4384156761 startingPage "102087" @default.
• W4384156761 abstract "BackgroundHigh treatment prices of new cancer drugs are a global public health challenge to patients and healthcare systems. Policymakers in the US and Europe are debating reforms to drug pricing. The objective of this study was to assess whether drug efficacy or epidemiological characteristics (prevalence, incidence, mortality) explain the gap in treatment prices between cancer and non-cancer drugs in the US, Germany, and Switzerland.MethodsThis cross-sectional study identified all new drugs approved in the US, Germany, and Switzerland between 2011 and 2020. Drug efficacy was extracted from pivotal trials, drug prices from public and commercial databases, and epidemiological characteristics from the Global Burden of Disease (GBD) 2019 study. We used regression models to explain drug prices with drug efficacy and epidemiological characteristics (prevalence, incidence, mortality).FindingsThe cohort included 181 drugs, including 68 (37.5%) drugs approved for treatment of cancer. A significant negative correlation was found between incidence/prevalence and treatment prices, and a significant positive correlation was observed between mortality and treatment prices for both, cancer and non-cancer drugs. A significant association between relative drug efficacy and treatment prices of drugs was observed, however, less pronounced for cancer drugs. Our regression estimates indicated that after adjusting for efficacy and epidemiological characteristics, cancer drugs were on average approximately three times more expensive compared to non-cancer drugs in all three countries, indicating a cancer premium; i.e., treatment prices of cancer drugs were on average USD 74,412 (95% CI [62,810; 86,015]) more expensive in the US compared to non-cancer drugs, USD 37,770 (95% CI [26,175; 49,367]) more expensive in Germany, and USD 32,801 (95% CI [27,048; 38,555]) more expensive in Switzerland. Our model explained 72% of the variance in observed prices (R2).InterpretationDrug pricing reforms should target the cancer premium to improve access of patients to cancer drugs as well as to achieve equity across the different therapeutic areas and sustainability in the health care systems.FundingThis study was funded by the Swiss National Science Foundation (SNSF, grant number PCEGP1_194607) and the Swiss Cancer Research Foundation (Krebsforschung Schweiz)." @default.
• W4384156761 created "2023-07-14" @default.
• W4384156761 creator A5017382091 @default.
• W4384156761 creator A5037689032 @default.
• W4384156761 creator A5045312027 @default.
• W4384156761 creator A5056969091 @default.
• W4384156761 creator A5068342025 @default.
• W4384156761 date "2023-07-01" @default.
• W4384156761 modified "2023-10-17" @default.
• W4384156761 title "The cancer premium – explaining differences in prices for cancer vs non-cancer drugs with efficacy and epidemiological endpoints in the US, Germany, and Switzerland: a cross sectional study" @default.
• W4384156761 cites W2027139388 @default.
• W4384156761 cites W2075037754 @default.
• W4384156761 cites W2131080517 @default.
• W4384156761 cites W2154111045 @default.
• W4384156761 cites W2519637787 @default.
• W4384156761 cites W2565587258 @default.
• W4384156761 cites W2600333833 @default.
• W4384156761 cites W2754725540 @default.
• W4384156761 cites W2907815516 @default.
• W4384156761 cites W2995127773 @default.
• W4384156761 cites W3009999522 @default.
• W4384156761 cites W3036447492 @default.
• W4384156761 cites W3045364476 @default.
• W4384156761 cites W3133955067 @default.
• W4384156761 cites W3157218996 @default.
• W4384156761 cites W3175714562 @default.
• W4384156761 cites W4220735963 @default.
• W4384156761 cites W4221014596 @default.
• W4384156761 cites W4280489560 @default.
• W4384156761 cites W4281869089 @default.
• W4384156761 cites W4292367066 @default.
• W4384156761 cites W4297242756 @default.
• W4384156761 cites W4307771765 @default.
• W4384156761 cites W4312194207 @default.
• W4384156761 cites W4365449883 @default.
• W4384156761 doi "https://doi.org/10.1016/j.eclinm.2023.102087" @default.
• W4384156761 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37521033" @default.
• W4384156761 hasPublicationYear "2023" @default.
• W4384156761 type Work @default.
• W4384156761 citedByCount "0" @default.
• W4384156761 crossrefType "journal-article" @default.
• W4384156761 hasAuthorship W4384156761A5017382091 @default.
• W4384156761 hasAuthorship W4384156761A5037689032 @default.
• W4384156761 hasAuthorship W4384156761A5045312027 @default.
• W4384156761 hasAuthorship W4384156761A5056969091 @default.
• W4384156761 hasAuthorship W4384156761A5068342025 @default.
• W4384156761 hasBestOaLocation W43841567611 @default.
• W4384156761 hasConcept C100001284 @default.
• W4384156761 hasConcept C107130276 @default.
• W4384156761 hasConcept C120665830 @default.
• W4384156761 hasConcept C121332964 @default.
• W4384156761 hasConcept C121608353 @default.
• W4384156761 hasConcept C126322002 @default.
• W4384156761 hasConcept C162324750 @default.
• W4384156761 hasConcept C2780035454 @default.
• W4384156761 hasConcept C2910862244 @default.
• W4384156761 hasConcept C3020340455 @default.
• W4384156761 hasConcept C61511704 @default.
• W4384156761 hasConcept C71924100 @default.
• W4384156761 hasConcept C98274493 @default.
• W4384156761 hasConceptScore W4384156761C100001284 @default.
• W4384156761 hasConceptScore W4384156761C107130276 @default.
• W4384156761 hasConceptScore W4384156761C120665830 @default.
• W4384156761 hasConceptScore W4384156761C121332964 @default.
• W4384156761 hasConceptScore W4384156761C121608353 @default.
• W4384156761 hasConceptScore W4384156761C126322002 @default.
• W4384156761 hasConceptScore W4384156761C162324750 @default.
• W4384156761 hasConceptScore W4384156761C2780035454 @default.
• W4384156761 hasConceptScore W4384156761C2910862244 @default.
• W4384156761 hasConceptScore W4384156761C3020340455 @default.
• W4384156761 hasConceptScore W4384156761C61511704 @default.
• W4384156761 hasConceptScore W4384156761C71924100 @default.
• W4384156761 hasConceptScore W4384156761C98274493 @default.
• W4384156761 hasFunder F4320320924 @default.
• W4384156761 hasFunder F4320327941 @default.
• W4384156761 hasLocation W43841567611 @default.
• W4384156761 hasLocation W43841567612 @default.
• W4384156761 hasLocation W43841567613 @default.
• W4384156761 hasOpenAccess W4384156761 @default.
• W4384156761 hasPrimaryLocation W43841567611 @default.
• W4384156761 hasRelatedWork W1698264213 @default.
• W4384156761 hasRelatedWork W1947307429 @default.
• W4384156761 hasRelatedWork W2102091262 @default.
• W4384156761 hasRelatedWork W2408973000 @default.
• W4384156761 hasRelatedWork W2765594136 @default.
• W4384156761 hasRelatedWork W2985793918 @default.
• W4384156761 hasRelatedWork W3205561628 @default.
• W4384156761 hasRelatedWork W4246776589 @default.
• W4384156761 hasRelatedWork W4298973622 @default.
• W4384156761 hasRelatedWork W4365449883 @default.
• W4384156761 hasVolume "61" @default.
• W4384156761 isParatext "false" @default.
• W4384156761 isRetracted "false" @default.
• W4384156761 workType "article" @default.